Pipelines
Product Pipelines
Hemogen, a subsidiary company of BGI Group, adheres to the vision of BGI - "Omics for All". Supported by the strong scientific research capabilities of BGI-Research and BGI Group's channel influence in the medical and health science field, Hemogen is committed to the treatment of hemoglobin diseases and to "Create A Thalassemia Free World Together".
- Program
- Indications
- Early R&D
- Preclinical
- IIT
- Phase I/II
- Phase III
- HGI-001
- Transfusion-dependent beta-thalassemia
- HGI-002
- Transfusion-dependent alpha-thalassaemia
- HGI-003
- Rare disease
- HGI-004
- Rare disease
- HGI-005
- Rare disease
